Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia (2022)

Peer-Reviewed Study · Dabira ED, Soumare HM, Conteh B, Ceesay F, Ndiath MO, Bradley J, Mohammed N, Kandeh B, et al. · April 2022

Dabira ED et al., 2022-04: Cluster-randomized trial in 32 Gambian villages where three monthly rounds of ivermectin plus dihydroartemisinin-piperaquine halved malaria prevalence at the end of the second year, but had no measurable effect on the mosquito parous rate.

In November 2019, malaria prevalence was 12·8% (324 of 2529) in the control group and 5·1% (140 of 2722) in the intervention group (odds ratio [OR] 0·30, 95% CI 0·16-0·59; p<0·001).

Dabira ED et al., 2022-04: Cluster-randomized trial in 32 Gambian villages where three monthly rounds of ivermectin plus dihydroartemisinin-piperaquine halved malaria prevalence at the end of the second year, but had no measurable effect on the mosquito parous rate. Open-label cluster-randomized controlled trial, 32 villages (16 per arm), 10,638 residents, Upper River region, The Gambia, two transmission seasons 2018-19; ivermectin 300-400 micrograms/kg/day orally for 3 consecutive days plus weight-dosed DP, once monthly for 3 rounds per season; comparator: standard control interventions only. Prevalence 5.1% vs 12.8% (OR 0.30); Anopheles gambiae parous rate 81.7% vs 83.1% (0.90, 0.66-1.25; p=0.537); 11 serious adverse events, none related. Funded by the Joint Global Health Trials Scheme (MRC). No competing interests declared. Bearing PARTLY SUPPORTS: human malaria prevalence fell while the prespecified entomological endpoint did not. Study type: randomized trial.